The difference in the hemodynamic performance of the earlier generation Sapien and CoreValve is well documented. Radcliffe Cardiology is part of Radcliffe Medical Media, an independent publisher and the Radcliffe Group Ltd. In addition to self-reported registry data, randomised data are available from the Placement of Aortic Transcatheter Valves (PARTNER) trial, which evaluated the ESV, and the CoreValve US Pivotal trial, which evaluated the MCV. Early survival was 93.4 % and one-year mortality was 17.1 %.

-, J Am Coll Cardiol. If the aortic root  dilates  for  some reason  which is very likely in  atherosclerotic  process    the very foundation of valve is shaken and para valvular leak is certain.

Although the rate of stroke following TAVI was higher at 5.1 % compared with 2.4 % following SAVR, this result did not reach statistical significance.

All rights reserved.

Effects of Combination Therapy with Cilostazol and Probucol versus Monotherapy with Cilostazol on Coronary Plaque, Lipid and Biomarkers: SECURE Study, a Double-Blind Randomized Controlled Clinical Trial. Fill in your details below or click an icon to log in: You are commenting using your WordPress.com account. In addition to annular diameter, a detailed assessment of cardiac anatomy is necessary as this can affect the choice of implant and method of delivery. Device success reached 91.9% and 95.4% in the SAPIEN S3 and Evolut-R groups, respectively (p = 0.289). Change ), You are commenting using your Google account. NIH Vinayak Bapat is a consultant for Edwards Lifesciences, Medtronic Inc and St. Jude Medical. Two devices in current use are the MCV and the ESV. Since the inception of TAVI in 2002, the two main devices in routine clinical use are the Edwards Sapien valve (since 2006) and the Medtronic CoreValve (since 2007). The presence of a bicuspid, unicuspid or non-calcified aortic valve, severe aortic regurgitation (AR) and a native annulus size that is too small or too big relative to available TAVI devices (currently unsuitable annulus sizes include <18 mm or >29 mm for a MCV prosthesisDownload originalDownload originalDownload original J Am Soc Echocardiogr. Bae JH, Kwon TG, Hyun DW, et al. The new balloon-expandable Edwards Sapien-3 (S3) valve offers several novel features to prevent or reduce typical TAVI-related problems such as paravalvular leaks (PVLs) and vascular complications. The retrospective Pooled Rotterdam - Milano Collaboration (PRAGMATIC) study compared the two valves and the recent Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis (CHOICE) study is the only randomised control trial of the two devices. ( Log Out /  General Indications for Aortic Valve Implantation Attenuated plaque detected by intravascular ultrasound: clinical, angiographic, and morphologic features and post-percutaneous coronary intervention complications in patients with acute coronary syndromes. Both valves are available in 23 mm and 26 mm sizes, although more recently, the Sapien XT has been introduced in a 29 mm size, enabling treatment of annular diameters between 18 and 27 mm. In cohort B, TAVI was compared with medical management (including balloon valvuloplasty) in inoperable patients with severe aortic stenosis. In this article we explore in detail the respective design features, related indications for each valve type as well as their known outcomes. A presentation from the Current data on TAVI outcomes session at ESC CONGRESS 2016 Tian J, Gu X, Sun Y, et al. Valve performance was evaluated by serial assessment of aortic valve mean pressure gradient (PG) and aortic valve area (AVA) assessments. CoreValve Versus Sapien ValveCHOICE Randomised Clinical Trial A prospective natural-history study of coronary atherosclerosis.

These results were an improvement on previous pre-dated registry data such as FRANCE-2 and the UK registry (see below).20. The aim The mean aortic PG decreased significantly from FPI to the 3-year follow-up point among patients with CoreValve; however, it was not significantly different from those with SAPIEN-XT. All-cause mortality at one-year was 14.2 % in the MCV group versus 19.1 % in the SAVR group. We use cookies to help provide and enhance our service and tailor content and ads. 2013;111(7):1026-1033.PubMed Google Scholar Crossref Risk of Annular Rupture Nakamura T, Kubo N, Ako J, Momomura S. Angiographic no-reflow phenomenon and plaque characteristics by virtual histology intravascular ultrasound in patients with acute myocardial infarction. In this study, long-term clinical outcomes for CoreValve and SAPIEN XT were similar. Garcìa-Garcìa HM, Gogas BD, Serruys PW, Bruining N. IVUS-based imaging modalities for tissue characterization: similarities and differences. During follow-up of 237 ± 138 days, all-cause mortality was higher in patients implanted with Evolut-R compared with SAPIEN S3 (7 vs 1 cases, respectively, p = 0.006), however, cardiovascular mortality was not significantly different between groups. Transfemoral delivery is facilitated via the RetroFlex 3 system, and the Ascendra system is used for transapical implantation. Rapid pacing is required during deployment as the valve is balloon expandable. The CoreValve Evolut-R has a retrievable/repositionable system to facilitate precise positioning and an extended skirt with modified cell geometry to reduce the risk of AR. The presence of a mitral valve prosthesis requires special consideration. runs in slow motion . Study population included 232 patients implanted with the SAPIEN S3 (n = 124) and Evolut-R (n = 108). The aim of this study was to investigate the potential differences in the clinical outcome compared to its predecessor Sapien XT (SXT). Notaristefano F, Reccia MR, Notaristefano S, Annunziata R, Sclafani R, Ambrosio G, Cavallini C. Cardiovasc Revasc Med. A total of 2,344 consecutive patients were enrolled in two cohorts to reflect trends overtime. Though both valves appear suitable .There are major differences in the concept , design , and technique of implantation . Cheng JM, Garcia-Garcia HM, de Boer SP, et al. Meta-analysis of plaque composition by intravascular ultrasound and its relation to distal embolization after percutaneous coronary intervention. In comparison with the Sapien and Sapien XT valve this has a lower crimp profile and an additional outer PET skirt to reduce paravalvular regurgitation. (Does it appear  foolish to expect the diseased  aorta to hold the valve in situ ? J Interv Cardiol 2007 Oct;20:335–9. Inconvenience caused is regretted. A report of the American College of Cardiology task force on clinical expert consensus documents. The presence of ilio-femoral tortuosities, kinks in the aorta, existing stents, aneurysms or thrombi are also contraindications for transfemoral access, and alternative access via the transapical, transaortic or subclavian route have to be considered. Patients enrolled into this cohort were deemed to have an operable risk of >50 %.